---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-06T17:40:41.470582'
end_time: '2026-02-06T17:48:40.244283'
duration_seconds: 478.77
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Scimitar Syndrome
  mondo_id: ''
  category: Complex
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 19
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Scimitar Syndrome
- **MONDO ID:**  (if available)
- **Category:** Complex

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Scimitar Syndrome**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Scimitar Syndrome
- **MONDO ID:**  (if available)
- **Category:** Complex

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Scimitar Syndrome**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


Disease Pathophysiology Research Template

Target Disease
- Disease Name: Scimitar Syndrome
- MONDO ID: Not established in sources retrieved
- Category: Complex congenital cardiopulmonary malformation

Executive summary and key concepts
Scimitar syndrome (also called hypogenetic lung or pulmonary venolobar syndrome) is a rare variant of partial anomalous pulmonary venous return (PAPVR) in which right pulmonary veins drain to the inferior vena cava (IVC), frequently accompanied by right lung hypoplasia, dextroposition of the heart, systemic arterial supply/bronchopulmonary sequestration, and associated intracardiac defects. The resultant left‑to‑right shunt produces pulmonary overcirculation; pulmonary hypertension (PH) arises via combined mechanisms: large shunt flow, reduced right‑sided pulmonary vascular bed from hypoplasia, systemic arterial collaterals, and pulmonary venous stenosis/obstruction. Infantile forms are typically symptomatic with higher PH risk; adult forms are often milder or incidental. Recent series emphasize multimodality imaging for anatomic definition and hemodynamic assessment to guide repair. (aristizabal2024clinicalcharacteristicsimaging pages 6-7, owususekyere2023scimitarsyndromein pages 2-4, aristizabal2024clinicalcharacteristicsimaging pages 3-6, cancemi2024congenitallungmalformations pages 15-18, ghandi2019scimitarsyndromepathology pages 3-5)

> "Scimitar syndrome is characterized by anomalous pulmonary venous drainage with a clinical triad of 'respiratory insufficiency, dextroposition of the heart, and hypoplasia of the right lung.'" https://doi.org/10.1007/s10554-024-03102-1 (aristizabal2024clinicalcharacteristicsimaging pages 6-7)
> "The anomaly produces an 'alteration in the relationship between pulmonary flow and systemic flow due to the presence of a left-to-right shunt' that drives pulmonary overcirculation and may necessitate hemodynamic assessment." https://doi.org/10.1007/s10554-024-03102-1 (aristizabal2024clinicalcharacteristicsimaging pages 6-7)
> "Multiple factors—large anomalous venous shunt, decreased right-sided vascular bed, systemic collaterals, and vein stenosis—contribute to pulmonary arterial hypertension in affected patients." https://doi.org/10.22038/ijp.2019.43898.3648 (ghandi2019scimitarsyndromepathology pages 3-5)
> "Pulmonary arterial hypertension is the key pathology in severe infant presentations; poor prognostic factors include stenosis of the anomalous veins, systemic arterial supply to the right lung, reduced right pulmonary vascular bed, and increased pulmonary blood flow." https://doi.org/10.4314/gmj.v57i4.9 (owususekyere2023scimitarsyndromein pages 2-4)
> "The 'scimitar sign'—a curvilinear anomalous vein along the right cardiac border—is visible on chest radiograph and was noted in ~82% of cases, while CT angiography with 3D/MIP reconstructions delineates anomalous drainage and collaterals." https://doi.org/10.1007/s10554-024-03102-1 (aristizabal2024clinicalcharacteristicsimaging pages 6-7)
> "Associated anomalies are common and in one series included horseshoe lung (36.4%), bronchopulmonary sequestration (36.4%), atrial septal defect (18.2%) and ventricular septal defect (27.3%)." https://doi.org/10.1007/s10554-024-03102-1 (aristizabal2024clinicalcharacteristicsimaging pages 3-6)
> "Echocardiography is the first-line test but may miss small or absent anomalous veins in infants; fetal echocardiography, CT angiography and MRA provide superior anatomic detail for diagnosis and surgical planning." https://doi.org/10.4314/gmj.v57i4.9 (owususekyere2023scimitarsyndromein pages 2-4)


*Blockquote: Direct, citable quotes summarizing core pathophysiology, hemodynamics, imaging hallmarks, associated anomalies, and diagnostic considerations for Scimitar syndrome from recent case series and reviews.*

1. Core pathophysiology
- Primary mechanisms
  - Anomalous pulmonary venous drainage: Right pulmonary veins connect to the IVC (the “scimitar vein”), creating a left‑to‑right shunt whose magnitude depends on the number of veins and resistance differences between vascular beds. This alters the relationship between pulmonary and systemic flow and can cause right‑sided volume overload. (aristizabal2024clinicalcharacteristicsimaging pages 6-7, aristizabal2024clinicalcharacteristicsimaging pages 3-6)
  - Right lung hypoplasia and reduced vascular bed: Hypoplasia diminishes the pulmonary arterial/venous network on the right, intensifying hemodynamic imbalance and predisposing to PH. (aristizabal2024clinicalcharacteristicsimaging pages 3-6, owususekyere2023scimitarsyndromein pages 2-4)
  - Systemic arterial supply/bronchopulmonary sequestration: Aberrant systemic arteries (including aortopulmonary collaterals or sequestration) add high‑pressure systemic inflow to the right lung, increasing pulmonary blood flow and heart volume load. (aristizabal2024clinicalcharacteristicsimaging pages 3-6, cancemi2024congenitallungmalformations pages 15-18)
  - Pulmonary venous stenosis/obstruction: Narrowing/obstruction of the scimitar vein or other pulmonary veins elevates post‑capillary pressure and promotes pulmonary vascular remodeling. (ghandi2019scimitarsyndromepathology pages 3-5)
  - Pulmonary hypertension pathways: Multiple converging factors—shunt size, reduced vascular bed, systemic collaterals, and venous stenosis—drive PH; infant presentations often exhibit severe PH with worse prognosis. (ghandi2019scimitarsyndromepathology pages 3-5, owususekyere2023scimitarsyndromein pages 2-4)

- Molecular pathways and cellular processes
  - Endothelial shear stress and flow signaling: Chronic overcirculation and abnormal venous pressure/flow likely activate endothelial mechanotransduction, promoting pulmonary vascular remodeling (endothelial dysfunction, smooth muscle cell hypertrophy). Although Scimitar‑specific molecular studies are limited, pediatric PH reviews contextualize these mechanisms. (ghandi2019scimitarsyndromepathology pages 3-5)
  - Developmental mechanisms: Faulty incorporation of the common pulmonary vein into the left atrium and abnormal venous patterning during early cardiopulmonary embryogenesis underlie PAPVR and scimitar variants; right lung hypoplasia reflects disrupted branching morphogenesis and vascular development. (cancemi2024congenitallungmalformations pages 15-18, singh2025alobelost pages 2-5)

- Hemodynamics and shunt physiology
  - Qp/Qs varies with extent of anomalous drainage; catheterization defines shunt magnitude, pulmonary artery pressures, and vascular resistance to guide intervention. Series report Qp/Qs ~1.2–1.9 with variable pressures; many have near‑normal PVR despite increased flow, supporting closure/redirect in selected cases. (aristizabal2024clinicalcharacteristicsimaging pages 3-6)

2. Key molecular players
- Genes/Proteins (implicated; limited direct genetic evidence)
  - Scimitar syndrome has sporadic occurrence; one cohort suggested STRC and CATSPER2 as possible contributors, but causal roles require confirmation. Genetic associations remain preliminary. (aristizabal2024clinicalcharacteristicsimaging pages 6-7)
- Chemical entities
  - No disease‑specific metabolites or drugs causally implicated in pathogenesis identified in recent sources; vasoactive therapies are used for associated PH per pediatric PH guidance. (ghandi2019scimitarsyndromepathology pages 3-5)
- Cell types (CL terms descriptive; IDs not in sources)
  - Pulmonary endothelial cells: central to shear‑stress responses and remodeling under high flow/venous hypertension. (ghandi2019scimitarsyndromepathology pages 3-5)
  - Vascular smooth muscle cells: medial hypertrophy in small pulmonary arteries with chronic overcirculation/venous obstruction. (ghandi2019scimitarsyndromepathology pages 3-5)
- Anatomical locations (UBERON terms descriptive)
  - Right lung (often hypoplastic), right pulmonary artery (often hypoplastic), pulmonary veins (right‑sided anomalous drainage), inferior vena cava (drainage site), right atrium/heart (volume load). (aristizabal2024clinicalcharacteristicsimaging pages 3-6, aristizabal2024clinicalcharacteristicsimaging pages 6-7, singh2025alobelost pages 2-5)

3. Biological processes (candidate GO mappings)
- Anomalous pulmonary venous drainage (abnormal pulmonary vein development/patterning). (aristizabal2024clinicalcharacteristicsimaging pages 6-7)
- Lung development/branching morphogenesis disrupted (right lung hypoplasia). (aristizabal2024clinicalcharacteristicsimaging pages 3-6, cancemi2024congenitallungmalformations pages 15-18)
- Regulation of pulmonary blood flow and response to shear stress; pulmonary vascular remodeling leading to increased pulmonary arterial pressure. (ghandi2019scimitarsyndromepathology pages 3-5)
- Systemic‑to‑pulmonary collateral circulation contributing to increased pulmonary blood flow. (aristizabal2024clinicalcharacteristicsimaging pages 3-6, cancemi2024congenitallungmalformations pages 15-18)

4. Cellular components
- Vascular endothelium and smooth muscle in small pulmonary arteries/arterioles (site of remodeling). (ghandi2019scimitarsyndromepathology pages 3-5)
- Pulmonary venous walls/scimitar vein (site of stenosis/obstruction). (ghandi2019scimitarsyndromepathology pages 3-5)
- Extracellular matrix in vessel wall contributing to remodeling. (ghandi2019scimitarsyndromepathology pages 3-5)

5. Disease progression
- Sequence of events
  1) Embryologic mispatterning of pulmonary venous connections, with failure/malposition of common pulmonary vein incorporation, plus ipsilateral lung hypoplasia. (cancemi2024congenitallungmalformations pages 15-18, singh2025alobelost pages 2-5)
  2) Postnatal hemodynamics: left‑to‑right shunt via scimitar vein; magnitude modulated by number of anomalous veins and resistances between vascular beds. (aristizabal2024clinicalcharacteristicsimaging pages 6-7)
  3) Compounding factors: systemic arterial collaterals or sequestration increase flow/pressure; potential scimitar vein stenosis raises venous pressures. (aristizabal2024clinicalcharacteristicsimaging pages 3-6, cancemi2024congenitallungmalformations pages 15-18, ghandi2019scimitarsyndromepathology pages 3-5)
  4) Vascular remodeling and PH: endothelial dysfunction and smooth muscle proliferation increase pulmonary vascular resistance; infants with large shunts/hypoplasia often develop PH early. (ghandi2019scimitarsyndromepathology pages 3-5, owususekyere2023scimitarsyndromein pages 2-4)
  5) Clinical trajectory: infants—respiratory insufficiency, failure to thrive, PH; adults—often incidental or mild symptoms unless significant shunt/PH evolves. (owususekyere2023scimitarsyndromein pages 2-4, singh2025alobelost pages 2-5)

- Stages or phenotypes
  - Infantile form: severe symptoms, frequent associated anomalies, higher PH and surgical need. (owususekyere2023scimitarsyndromein pages 2-4, aristizabal2024clinicalcharacteristicsimaging pages 3-6)
  - Adult form: milder/asymptomatic, incidental radiographic discovery; PH may develop later in incomplete variants. (singh2025alobelost pages 2-5)

6. Phenotypic manifestations and imaging
- Clinical phenotypes (HP)
  - Pulmonary hypoplasia (right), dextroposition/dextrocardia, respiratory insufficiency in infants, recurrent infections, exertional dyspnea, and pulmonary hypertension. (owususekyere2023scimitarsyndromein pages 2-4, aristizabal2024clinicalcharacteristicsimaging pages 3-6, ghandi2019scimitarsyndromepathology pages 3-5)
- Imaging hallmarks
  - Chest radiograph: “scimitar sign” curved anomalous vein along right cardiac border; frequency in one series ~82% overall, but lower in infants (<10% reported in literature). (aristizabal2024clinicalcharacteristicsimaging pages 6-7, owususekyere2023scimitarsyndromein pages 2-4)
  - CT angiography/MRA: delineates anomalous venous drainage (suprahepatic IVC common), right lung hypoplasia, dextroposition, right pulmonary artery hypoplasia, systemic arterial supply/sequestration, mosaic perfusion in PH. (aristizabal2024clinicalcharacteristicsimaging pages 3-6, cancemi2024congenitallungmalformations pages 15-18)
  - Echocardiography: first‑line, but limited for small/atretic veins in infants; catheterization quantifies Qp/Qs and PVR. Prenatal echocardiography can detect scimitar features and inform perinatal planning. (owususekyere2023scimitarsyndromein pages 2-4, aristizabal2024clinicalcharacteristicsimaging pages 3-6)

7. Associated anomalies and comorbidities
- Frequent: atrial septal defect (ASD), ventricular septal defect (VSD), right pulmonary artery hypoplasia, bronchopulmonary sequestration, horseshoe lung, vascular rings/aberrant subclavian in some cases. (aristizabal2024clinicalcharacteristicsimaging pages 3-6, gładki2023casereporta pages 7-7)

Applications and real‑world implementations (diagnostics and management)
- Multimodality imaging algorithms increasingly rely on CT angiography with 3D/MIP reconstructions to map anomalous veins and systemic collaterals and to plan surgical or endovascular interventions; echocardiography and MRI complement anatomy and functional assessment; catheterization guides hemodynamic decisions (Qp/Qs, PVR). (aristizabal2024clinicalcharacteristicsimaging pages 6-7, aristizabal2024clinicalcharacteristicsimaging pages 3-6, cancemi2024congenitallungmalformations pages 15-18)
- Prenatal echocardiography can identify right‑sided scimitar features and associated anomalies and has been associated with favorable postoperative outcomes in small series. (owususekyere2023scimitarsyndromein pages 2-4)
- Management pathways are phenotype‑stratified: infantile symptomatic forms with significant shunt/PH often undergo surgical redirection/repair and, when present, management of systemic collaterals or sequestration; adults with minimal shunt may be observed. Pediatric PH guidance informs adjunctive therapy when PH persists. (aristizabal2024clinicalcharacteristicsimaging pages 3-6, ghandi2019scimitarsyndromepathology pages 3-5)

Expert opinions and analyses
- Institutional series emphasize that the hemodynamic burden is primarily determined by shunt magnitude and vascular bed/resistance mismatch; thus, an individualized, multidisciplinary approach is needed, with surgery for significant hemodynamic repercussions and medical management for mild to moderate cases. (aristizabal2024clinicalcharacteristicsimaging pages 6-7, aristizabal2024clinicalcharacteristicsimaging pages 3-6)
- Pediatric PH experts underscore that structural congenital lesions (including Scimitar syndrome) drive PH via pulmonary vascular remodeling, warranting early detection and tailored therapy; risk stratification and algorithms increasingly address CHD‑associated PH. (ghandi2019scimitarsyndromepathology pages 3-5)

Relevant statistics and data (recent)
- In a 2011–2022 tertiary‑center series (n=11), features included: scimitar sign on radiograph 81.8%; dextroposition 54.6%; pulmonary hypoplasia 54.6%; right pulmonary artery hypoplasia 45.5%; aortopulmonary collaterals 27.3%; horseshoe lung 36.4%; bronchopulmonary sequestration 36.4%; ASD 18.2%; VSD 27.3%; pulmonary hypertension 18.2%; 63.6% required surgical management. (aristizabal2024clinicalcharacteristicsimaging pages 3-6)
- Prognostic factors for severe infant cases: stenosis of anomalous veins, systemic arterial supply, reduced right pulmonary vascular bed, and increased pulmonary blood flow due to anomalous drainage or intracardiac lesion. (owususekyere2023scimitarsyndromein pages 2-4)

Ontology‑aligned annotations for knowledge base
- Gene/Protein (HGNC): No validated causative genes; tentative signals (STRC, CATSPER2) reported but unconfirmed. (aristizabal2024clinicalcharacteristicsimaging pages 6-7)
- Biological Processes (GO; descriptive terms): anomalous pulmonary vein development; lung development/branching morphogenesis; response to shear stress; pulmonary vascular remodeling; regulation of pulmonary artery pressure. (ghandi2019scimitarsyndromepathology pages 3-5, cancemi2024congenitallungmalformations pages 15-18)
- Cell Types (CL; descriptive): pulmonary endothelial cell; vascular smooth muscle cell. (ghandi2019scimitarsyndromepathology pages 3-5)
- Cellular Components: vascular endothelium; venous/arterial walls; extracellular matrix. (ghandi2019scimitarsyndromepathology pages 3-5)
- Phenotypes (HP; descriptive): HP:0006530 Pulmonary hypoplasia; HP:0004935 Pulmonary hypertension; HP:0001651 Dextrocardia/dextroposition. (owususekyere2023scimitarsyndromein pages 2-4, aristizabal2024clinicalcharacteristicsimaging pages 3-6)
- Anatomical Locations (UBERON; descriptive): UBERON:0002048 Right lung; UBERON:0001637 Inferior vena cava; UBERON:0002049 Pulmonary vein; UBERON:0001516 Right atrium. (aristizabal2024clinicalcharacteristicsimaging pages 3-6, aristizabal2024clinicalcharacteristicsimaging pages 6-7)
- Chemical Entities (CHEBI): Not applicable based on current evidence.

| Category | Entity/Term | Ontology Identifier (if applicable) | Role in Pathophysiology | Evidence/Citation |
|---|---|---|---|---|
| Cell type | Pulmonary endothelial cell | N/A | Mediates flow-dependent signaling and pulmonary vascular remodeling in response to abnormal venous return and increased pulmonary flow | (cancemi2024congenitallungmalformations pages 15-18, ghandi2019scimitarsyndromepathology pages 3-5) |
| Cell type | Vascular smooth muscle cell | N/A | Undergoes hypertrophy and contributes to increased pulmonary vascular resistance in pulmonary hypertension secondary to chronic overcirculation or vein obstruction | (ghandi2019scimitarsyndromepathology pages 3-5, cancemi2024congenitallungmalformations pages 15-18) |
| Anatomical site | Right lung | N/A | Frequently hypoplastic in Scimitar syndrome, reducing pulmonary vascular bed and exacerbating hemodynamic imbalance | (aristizabal2024clinicalcharacteristicsimaging pages 3-6, owususekyere2023scimitarsyndromein pages 2-4) |
| Anatomical site | Inferior vena cava (IVC) | N/A | Usual drainage target for the anomalous right pulmonary veins (the "scimitar" vein), producing a left-to-right shunt | (aristizabal2024clinicalcharacteristicsimaging pages 3-6, aristizabal2024clinicalcharacteristicsimaging pages 6-7) |
| Anatomical site | Right pulmonary artery | N/A | Often hypoplastic or reduced-caliber, reflecting diminished pulmonary arterial supply to the affected lung and influencing perfusion/pressure dynamics | (aristizabal2024clinicalcharacteristicsimaging pages 3-6, singh2025alobelost pages 2-5) |
| Anatomical site | Pulmonary veins | N/A | Site of anomalous connection and potential stenosis/obstruction; venous pathology contributes to pulmonary venous hypertension and remodeling | (aristizabal2024clinicalcharacteristicsimaging pages 6-7, ghandi2019scimitarsyndromepathology pages 3-5) |
| Anatomical site | Right atrium / heart | N/A | Receives excess systemic return from anomalous vein leading to volume overload, chamber dilation and sequelae | (aristizabal2024clinicalcharacteristicsimaging pages 6-7, aristizabal2024clinicalcharacteristicsimaging pages 3-6) |
| Process | Left-to-right shunt | N/A | Hemodynamic consequence of anomalous pulmonary venous drainage; magnitude determines pulmonary overcirculation and need for intervention | (aristizabal2024clinicalcharacteristicsimaging pages 6-7, aristizabal2024clinicalcharacteristicsimaging pages 3-6) |
| Process | Pulmonary vascular remodeling / PH risk | N/A | Chronic increased flow, reduced vascular bed, systemic collaterals, or venous stenosis promote medial hypertrophy, intimal change and PAH | (ghandi2019scimitarsyndromepathology pages 3-5, aristizabal2024clinicalcharacteristicsimaging pages 6-7) |
| Process | Lung hypoplasia | N/A | Developmental reduction in lung parenchyma and vasculature on the affected side, central to the syndrome's respiratory and hemodynamic features | (aristizabal2024clinicalcharacteristicsimaging pages 3-6, cancemi2024congenitallungmalformations pages 15-18) |
| Process | Anomalous pulmonary venous drainage | N/A | Primary embryologic/structural defect: pulmonary veins (usually right-sided) drain to systemic venous circulation rather than left atrium | (aristizabal2024clinicalcharacteristicsimaging pages 6-7, aristizabal2024clinicalcharacteristicsimaging pages 3-6) |
| Process | Systemic arterial supply / bronchopulmonary sequestration | N/A | Aberrant systemic arteries (sequestration or collaterals) supply part of the right lung, adding systemic-to-pulmonary flow and complicating management | (aristizabal2024clinicalcharacteristicsimaging pages 3-6, cancemi2024congenitallungmalformations pages 15-18) |
| Phenotype | Dextroposition (cardiac shift) | N/A | Rightward displacement of the heart secondary to reduced right lung volume and altered thoracic anatomy | (aristizabal2024clinicalcharacteristicsimaging pages 6-7, aristizabal2024clinicalcharacteristicsimaging pages 3-6) |
| Phenotype | Pulmonary hypoplasia | N/A | Clinical/radiographic manifestation of underdeveloped right lung; correlates with severity and infantile presentations | (aristizabal2024clinicalcharacteristicsimaging pages 3-6, owususekyere2023scimitarsyndromein pages 2-4) |
| Phenotype | Pulmonary hypertension | N/A | Frequent complication driven by shunt, reduced vascular bed and vein stenosis; major determinant of prognosis, especially in infants | (ghandi2019scimitarsyndromepathology pages 3-5, owususekyere2023scimitarsyndromein pages 2-4) |
| Associated anomaly | Horseshoe lung | N/A | Fusion/abnormal connection of lung parenchyma that co-occurs with Scimitar features in reported series | (aristizabal2024clinicalcharacteristicsimaging pages 3-6, ghandi2019scimitarsyndromepathology pages 3-5) |
| Associated anomaly | Atrial septal defect (ASD) | N/A | Common intracardiac defect coexisting with PAPVR/Scimitar syndrome and contributing to shunt physiology | (aristizabal2024clinicalcharacteristicsimaging pages 3-6, gładki2023casereporta pages 7-7) |
| Associated anomaly | Ventricular septal defect (VSD) | N/A | Reported concomitant cardiac lesion that may modify hemodynamics and clinical presentation | (aristizabal2024clinicalcharacteristicsimaging pages 3-6, gładki2023casereporta pages 7-7) |


*Table: Structured, ontology-aligned summary of key cell types, anatomical sites, processes, phenotypes, and associated anomalies in Scimitar syndrome, with evidence pointers to the gathered literature (pqac IDs). This table supports knowledge-base annotation and mechanistic interpretation.*

Evidence items (with URLs and publication dates)
- Aristizabal AM et al. Clinical characteristics, imaging findings, management, and outcomes of patients with scimitar syndrome at a tertiary referral healthcare center in Colombia. Int J Cardiovasc Imaging. 2024 Apr;40:1319–1328. doi:10.1007/s10554-024-03102-1. URL: https://doi.org/10.1007/s10554-024-03102-1 (aristizabal2024clinicalcharacteristicsimaging pages 3-6, aristizabal2024clinicalcharacteristicsimaging pages 6-7)
- Owusu‑Sekyere F et al. Scimitar syndrome in a four‑month‑old infant. Ghana Med J. 2023 Dec;57(4):316–320. doi:10.4314/gmj.v57i4.9. URL: https://doi.org/10.4314/gmj.v57i4.9 (owususekyere2023scimitarsyndromein pages 2-4)
- Cancemi G et al. Congenital lung malformations: a pictorial review of imaging findings and a practical guide for diagnosis. Children. 2024 May;11(6):638. doi:10.3390/children11060638. URL: https://doi.org/10.3390/children11060638 (cancemi2024congenitallungmalformations pages 15-18)
- Ghandi Y, Farsi A. Scimitar Syndrome: Pathology, Clinical Presentation, Radiographic Features, and Treatment. Int J Pediatr. 2019 Dec;7:10611–10620. doi:10.22038/ijp.2019.43898.3648. URL: https://doi.org/10.22038/ijp.2019.43898.3648 (ghandi2019scimitarsyndromepathology pages 3-5)
- Singh AK et al. A lobe lost and a vein misplaced: an adult’s tale of scimitar syndrome. Egyptian J Bronchology. 2025 Dec. doi:10.1186/s43168-025-00500-4. URL: https://doi.org/10.1186/s43168-025-00500-4 (singh2025alobelost pages 2-5, singh2025alobelost pages 1-2)
- Gładki M et al. Case report: a unique quadruple coexisting anomaly—scimitar syndrome, atrial septal defect, vascular ring, and pulmonary sequestration. Front Pediatr. 2023 Jul. doi:10.3389/fped.2023.1214900. URL: https://doi.org/10.3389/fped.2023.1214900 (gładki2023casereporta pages 7-7)

Limitations and open questions
- Genetic underpinnings remain unclear; occasional reports suggest candidate loci, but robust causality is lacking. Dedicated genomic studies in PAPVR/Scimitar cohorts are needed. (aristizabal2024clinicalcharacteristicsimaging pages 6-7)
- Molecular‑cellular remodeling mechanisms are inferred from pediatric PH paradigms; direct tissue‑level studies in Scimitar syndrome are scarce.

Plan status: Completed tasks include literature synthesis, evidence extraction, ontology mapping, and artifact creation; report submitted with prioritized 2023–2024 sources and direct quotes where available. (aristizabal2024clinicalcharacteristicsimaging pages 6-7, owususekyere2023scimitarsyndromein pages 2-4, aristizabal2024clinicalcharacteristicsimaging pages 3-6, cancemi2024congenitallungmalformations pages 15-18, ghandi2019scimitarsyndromepathology pages 3-5, gładki2023casereporta pages 7-7, singh2025alobelost pages 1-2)

References

1. (aristizabal2024clinicalcharacteristicsimaging pages 6-7): Ana M. Aristizabal, Carlos A. Guzmán-Serrano, Nancy Vanessa Mondol-Villamil, Lina Maria Bolaños-Vallejo, Valentina Mejia-Quiñones, Maria Alejandra Recio-Gómez, Enrique Carlos García-Pretelt, Mauricio Mejía-González, Walter Mosquera Alvarez, and Jaiber Alberto Gutiérrez-Gil. Clinical characteristics, imaging findings, management, and outcomes of patients with scimitar syndrome at a tertiary referral healthcare center in colombia. The International Journal of Cardiovascular Imaging, 40:1319-1328, Apr 2024. URL: https://doi.org/10.1007/s10554-024-03102-1, doi:10.1007/s10554-024-03102-1. This article has 5 citations.

2. (owususekyere2023scimitarsyndromein pages 2-4): Frank Owusu-Sekyere, Victoria M. Adabayeri, Efua Otoo, Claudia Adja-Sai, and Akosua M. Boateng. Scimitar syndrome in a four-month-old infant. Ghana Medical Journal, 57:316-320, Dec 2023. URL: https://doi.org/10.4314/gmj.v57i4.9, doi:10.4314/gmj.v57i4.9. This article has 2 citations.

3. (aristizabal2024clinicalcharacteristicsimaging pages 3-6): Ana M. Aristizabal, Carlos A. Guzmán-Serrano, Nancy Vanessa Mondol-Villamil, Lina Maria Bolaños-Vallejo, Valentina Mejia-Quiñones, Maria Alejandra Recio-Gómez, Enrique Carlos García-Pretelt, Mauricio Mejía-González, Walter Mosquera Alvarez, and Jaiber Alberto Gutiérrez-Gil. Clinical characteristics, imaging findings, management, and outcomes of patients with scimitar syndrome at a tertiary referral healthcare center in colombia. The International Journal of Cardiovascular Imaging, 40:1319-1328, Apr 2024. URL: https://doi.org/10.1007/s10554-024-03102-1, doi:10.1007/s10554-024-03102-1. This article has 5 citations.

4. (cancemi2024congenitallungmalformations pages 15-18): Giovanna Cancemi, Giulio Distefano, Gioele Vitaliti, Dario Milazzo, Giuseppe Terzo, Giuseppe Belfiore, Vincenzo Di Benedetto, Maria Grazia Scuderi, Maria Coronella, Andrea Giovanni Musumeci, Daniele Grippaldi, Letizia Antonella Mauro, Pietro Valerio Foti, Antonio Basile, and Stefano Palmucci. Congenital lung malformations: a pictorial review of imaging findings and a practical guide for diagnosis. Children, 11:638, May 2024. URL: https://doi.org/10.3390/children11060638, doi:10.3390/children11060638. This article has 12 citations and is from a poor quality or predatory journal.

5. (ghandi2019scimitarsyndromepathology pages 3-5): Y. Ghandi and A. Farsi. Scimitar syndrome: pathology, clinical presentation, radiographic features, and treatment. International Journal of Pediatrics, 7:10611-10620, Dec 2019. URL: https://doi.org/10.22038/ijp.2019.43898.3648, doi:10.22038/ijp.2019.43898.3648. This article has 1 citations and is from a poor quality or predatory journal.

6. (singh2025alobelost pages 2-5): Anil Kumar Singh, Huda Shamim, Rahul Sharma, and Rajat Kumar Mishra. A lobe lost and a vein misplaced: an adult’s tale of scimitar syndrome. The Egyptian Journal of Bronchology, Dec 2025. URL: https://doi.org/10.1186/s43168-025-00500-4, doi:10.1186/s43168-025-00500-4. This article has 0 citations.

7. (gładki2023casereporta pages 7-7): Marcin Gładki, Paweł R. Bednarek, and Wojciech Owecki. Case report: a unique quadruple coexisting anomaly—scimitar syndrome, atrial septal defect, vascular ring, and pulmonary sequestration. Frontiers in Pediatrics, Jul 2023. URL: https://doi.org/10.3389/fped.2023.1214900, doi:10.3389/fped.2023.1214900. This article has 0 citations and is from a poor quality or predatory journal.

8. (singh2025alobelost pages 1-2): Anil Kumar Singh, Huda Shamim, Rahul Sharma, and Rajat Kumar Mishra. A lobe lost and a vein misplaced: an adult’s tale of scimitar syndrome. The Egyptian Journal of Bronchology, Dec 2025. URL: https://doi.org/10.1186/s43168-025-00500-4, doi:10.1186/s43168-025-00500-4. This article has 0 citations.